In summary, our data support a model by which cancer-driven protumoral myelopoiesis is regulated by a circuit in which tumor derived factors induce the production of CCL3 and CCL4 and other CCR1 and CCR5 ligands that, by engaging CCR1 and CCR5, autocrinally promote their differentiation into MDSCs. This evidence concerns the gene CCR5 and neoplasm.